Loading…
Invariant p53 immunostaining in primary and recurrent breast cancer
In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expressio...
Saved in:
Published in: | European journal of cancer (1990) 2004-01, Vol.40 (1), p.28-32 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33 |
---|---|
cites | cdi_FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33 |
container_end_page | 32 |
container_issue | 1 |
container_start_page | 28 |
container_title | European journal of cancer (1990) |
container_volume | 40 |
creator | Poelman, S.M. Heimann, R. Fleming, G.F. Recant, W.M. Conzen, S.D. |
description | In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expression. We therefore evaluated p53 expression in paired primary and recurrent breast tumours: 48% of primary and 32% of recurrent tumours had abnormally increased p53 expression. Of the paired samples, 84% showed no change in p53 expression between the primary tumour and the metastasis. In fact, in no case was low (normal) p53 expression in the primary tumour followed by the development of high (aberrant) p53 expression in the recurrence. These results show that increased p53 expression is not selected for in the malignant cells emerging following adjuvant therapy, suggesting that p53 expression is unlikely to play a central role in breast cancer recurrences. |
doi_str_mv | 10.1016/S0959-8049(03)00661-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80071595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804903006610</els_id><sourcerecordid>80071595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33</originalsourceid><addsrcrecordid>eNqF0E1P3DAQgGELUcGy5ScU5UJVDmlnHDuxT6haFYqE1EPL2XKcSWW0cRY7Qeq_r5eN4MjJPjz-mJexTwhfEbD-9hu01KUCob9AdQVQ11jCEVuhanQJSvJjtnolp-wspUcAaJSAE3aKolZNo-oV29yFZxu9DVOxk1Xhh2EOY5qsDz78LXwodtEPNv4rbOiKSG6OkbJtI9k0Fc4GR_Ej-9DbbaLzZV2zh5sffzY_y_tft3eb7_elE5xPJVmlhHQkuCIreYWoeykklwJ1B31ve00SZUt9LVrdtVYjdnXTio4jOldVa_b5cO8ujk8zpckMPjnabm2gcU5G5flQavkuRM1rQNAZygN0cUwpUm-WcQ2C2Wc2L5nNvqGByrxkzps1u1gemNuBurdTS9cMLhdgk7PbPuZQPr05KUAi8OyuD45yt2dP0STnKUftfI49mW7073zlP2iYmPo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19260109</pqid></control><display><type>article</type><title>Invariant p53 immunostaining in primary and recurrent breast cancer</title><source>ScienceDirect Freedom Collection</source><creator>Poelman, S.M. ; Heimann, R. ; Fleming, G.F. ; Recant, W.M. ; Conzen, S.D.</creator><creatorcontrib>Poelman, S.M. ; Heimann, R. ; Fleming, G.F. ; Recant, W.M. ; Conzen, S.D.</creatorcontrib><description>In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expression. We therefore evaluated p53 expression in paired primary and recurrent breast tumours: 48% of primary and 32% of recurrent tumours had abnormally increased p53 expression. Of the paired samples, 84% showed no change in p53 expression between the primary tumour and the metastasis. In fact, in no case was low (normal) p53 expression in the primary tumour followed by the development of high (aberrant) p53 expression in the recurrence. These results show that increased p53 expression is not selected for in the malignant cells emerging following adjuvant therapy, suggesting that p53 expression is unlikely to play a central role in breast cancer recurrences.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(03)00661-0</identifier><identifier>PMID: 14687786</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvant chemotherapy ; Adult ; Aged ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - metabolism ; Cyclin-Dependent Kinase Inhibitor p21 ; Cyclins - metabolism ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry - methods ; Mammary gland diseases ; Medical sciences ; Metastasis ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - metabolism ; p21 ; p53 ; Pharmacology. Drug treatments ; Recurrence ; Tumor Suppressor Protein p53 - metabolism ; Tumors</subject><ispartof>European journal of cancer (1990), 2004-01, Vol.40 (1), p.28-32</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33</citedby><cites>FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15405102$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14687786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poelman, S.M.</creatorcontrib><creatorcontrib>Heimann, R.</creatorcontrib><creatorcontrib>Fleming, G.F.</creatorcontrib><creatorcontrib>Recant, W.M.</creatorcontrib><creatorcontrib>Conzen, S.D.</creatorcontrib><title>Invariant p53 immunostaining in primary and recurrent breast cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expression. We therefore evaluated p53 expression in paired primary and recurrent breast tumours: 48% of primary and 32% of recurrent tumours had abnormally increased p53 expression. Of the paired samples, 84% showed no change in p53 expression between the primary tumour and the metastasis. In fact, in no case was low (normal) p53 expression in the primary tumour followed by the development of high (aberrant) p53 expression in the recurrence. These results show that increased p53 expression is not selected for in the malignant cells emerging following adjuvant therapy, suggesting that p53 expression is unlikely to play a central role in breast cancer recurrences.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cyclin-Dependent Kinase Inhibitor p21</subject><subject>Cyclins - metabolism</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>p21</subject><subject>p53</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqF0E1P3DAQgGELUcGy5ScU5UJVDmlnHDuxT6haFYqE1EPL2XKcSWW0cRY7Qeq_r5eN4MjJPjz-mJexTwhfEbD-9hu01KUCob9AdQVQ11jCEVuhanQJSvJjtnolp-wspUcAaJSAE3aKolZNo-oV29yFZxu9DVOxk1Xhh2EOY5qsDz78LXwodtEPNv4rbOiKSG6OkbJtI9k0Fc4GR_Ej-9DbbaLzZV2zh5sffzY_y_tft3eb7_elE5xPJVmlhHQkuCIreYWoeykklwJ1B31ve00SZUt9LVrdtVYjdnXTio4jOldVa_b5cO8ujk8zpckMPjnabm2gcU5G5flQavkuRM1rQNAZygN0cUwpUm-WcQ2C2Wc2L5nNvqGByrxkzps1u1gemNuBurdTS9cMLhdgk7PbPuZQPr05KUAi8OyuD45yt2dP0STnKUftfI49mW7073zlP2iYmPo</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Poelman, S.M.</creator><creator>Heimann, R.</creator><creator>Fleming, G.F.</creator><creator>Recant, W.M.</creator><creator>Conzen, S.D.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200401</creationdate><title>Invariant p53 immunostaining in primary and recurrent breast cancer</title><author>Poelman, S.M. ; Heimann, R. ; Fleming, G.F. ; Recant, W.M. ; Conzen, S.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cyclin-Dependent Kinase Inhibitor p21</topic><topic>Cyclins - metabolism</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>p21</topic><topic>p53</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poelman, S.M.</creatorcontrib><creatorcontrib>Heimann, R.</creatorcontrib><creatorcontrib>Fleming, G.F.</creatorcontrib><creatorcontrib>Recant, W.M.</creatorcontrib><creatorcontrib>Conzen, S.D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poelman, S.M.</au><au>Heimann, R.</au><au>Fleming, G.F.</au><au>Recant, W.M.</au><au>Conzen, S.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Invariant p53 immunostaining in primary and recurrent breast cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2004-01</date><risdate>2004</risdate><volume>40</volume><issue>1</issue><spage>28</spage><epage>32</epage><pages>28-32</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following chemotherapy. The aim of this study was to test the hypothesis that breast cancer recurrences following adjuvant therapy exhibit aberrant p53 expression. We therefore evaluated p53 expression in paired primary and recurrent breast tumours: 48% of primary and 32% of recurrent tumours had abnormally increased p53 expression. Of the paired samples, 84% showed no change in p53 expression between the primary tumour and the metastasis. In fact, in no case was low (normal) p53 expression in the primary tumour followed by the development of high (aberrant) p53 expression in the recurrence. These results show that increased p53 expression is not selected for in the malignant cells emerging following adjuvant therapy, suggesting that p53 expression is unlikely to play a central role in breast cancer recurrences.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14687786</pmid><doi>10.1016/S0959-8049(03)00661-0</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0959-8049 |
ispartof | European journal of cancer (1990), 2004-01, Vol.40 (1), p.28-32 |
issn | 0959-8049 1879-0852 |
language | eng |
recordid | cdi_proquest_miscellaneous_80071595 |
source | ScienceDirect Freedom Collection |
subjects | Adjuvant chemotherapy Adult Aged Biological and medical sciences Breast cancer Breast Neoplasms - metabolism Cyclin-Dependent Kinase Inhibitor p21 Cyclins - metabolism Female Gynecology. Andrology. Obstetrics Humans Immunohistochemistry - methods Mammary gland diseases Medical sciences Metastasis Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - metabolism p21 p53 Pharmacology. Drug treatments Recurrence Tumor Suppressor Protein p53 - metabolism Tumors |
title | Invariant p53 immunostaining in primary and recurrent breast cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Invariant%20p53%20immunostaining%20in%20primary%20and%20recurrent%20breast%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Poelman,%20S.M.&rft.date=2004-01&rft.volume=40&rft.issue=1&rft.spage=28&rft.epage=32&rft.pages=28-32&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(03)00661-0&rft_dat=%3Cproquest_cross%3E80071595%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-ea8845ce428ea523119f54525419d0ffaf9e515bef64b9dba911d67b4d211cc33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19260109&rft_id=info:pmid/14687786&rfr_iscdi=true |